Iovance Biotherapeutics Inc (LTS:0JDK)
$ 11.51 0.295 (2.68%) Market Cap: 3.48 Bil Enterprise Value: 3.15 Bil PE Ratio: 0 PB Ratio: 4.43 GF Score: 30/100

Q2 2024 Iovance Biotherapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 08:30PM GMT
Release Date Price: $7.81 (+6.87%)
Operator

Welcome to the Iovance Biotherapeutics conference call to discuss second quarter 2024 results and recent corporate updates. My name is Daniel, and I will be your operator for today's call.

At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session. Please note that this conference is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin.

Sara Pellegrino
Iovance Biotherapeutics Inc - Senior Vice President, Investor Relations

Thank you, operator. Good afternoon and welcome to Iovance conference call and webcast to discuss our second quarter and first half 2024 results and corporate update. Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide an introduction and summarize key updates for our US commercial launch of Amtagvi including revenue guidance and our pipeline programs.

Jim Ziegler, EVP Commercial, will highlight additional details of the US

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot